bioMérieux Launches GENE-UP® TYPER,an Innovative Diagnostic Solution for Food Industries to Rapidly Analyze the Root Causeof Contamination of Listeria monocytogenes
MWN-AI** Summary
bioMérieux, a leader in in vitro diagnostics, has unveiled GENE-UP® TYPER, an advanced real-time PCR solution aimed at the food industry. This innovative diagnostic tool addresses the urgent need for rapid identification and analysis of Listeria monocytogenes contamination, a significant cause of foodborne illness that affects an estimated 600 million people annually according to the World Health Organization.
The GENE-UP® TYPER system enables food manufacturers to quickly determine the root cause of pathogen outbreaks. By utilizing rapid strain characterization, it provides essential data to help trace contamination sources, thus minimizing health risks and preventing costly recalls. Following the initial detection of pathogens, the system extracts and amplifies DNA before utilizing the AUGMENTED-DX web application. This application employs machine learning algorithms and a comprehensive genomic database to group and identify strains, progressively establishing a historical record of strain clusters and enhancing production process control.
With over 30 years of experience in industrial applications, bioMérieux is committed to advancing food safety through innovation and technology. Yasha Mitrotti, Executive Vice President of Industrial Applications at bioMérieux, emphasized the company’s dedication to reshaping food safety standards and enhancing consumer health.
The GENE-UP® TYPER LMO assay for Listeria monocytogenes is now available globally, in collaboration with Mérieux NutriSciences, which holds co-exclusive rights in selected geographies for outsourced testing services. This partnership reinforces bioMérieux’s mission to provide essential diagnostic solutions for food safety, ultimately striving to enhance public health and combat food insecurity.
BioMérieux’s commitment to the food industry reflects its broader vision for diagnostic excellence, with total revenues reported at €3.7 billion in 2023, highlighting its significant global presence in the field.
MWN-AI** Analysis
The recent launch of bioMérieux's GENE-UP® TYPER represents a significant advancement in the food safety diagnostics sector. Aimed particularly at the food industry, this innovative real-time PCR solution facilitates rapid strain characterization of Listeria monocytogenes, effectively helping food manufacturers identify and mitigate contamination sources.
With approximately 600 million foodborne illnesses globally each year as reported by the World Health Organization, this technological advancement is timely. Companies in the food sector bear heavy operational and reputational costs due to contamination incidents. GENE-UP® TYPER addresses this challenge by not only streamlining detection but also optimizing corrective action processes through root cause analysis.
Investors should view this launch positively given bioMérieux's long-standing industry presence and commitment to emerging technology. The integration of machine learning and a comprehensive genomic database in the GENE-UP® TYPER allows for enhanced data utilization, creating a competitive edge in pathogen detection. This ability to quickly trace back contamination sources is invaluable for manufacturers seeking to maintain stringent food safety standards and reduce operational disruptions.
From a market perspective, companies that adopt such advanced solutions could see enhanced operational efficiencies and minimized risk of costly recalls. Furthermore, as food safety regulations tighten globally, the demand for robust diagnostic systems is expected to rise, positioning bioMérieux favorably within this expanding market.
For investors, keeping an eye on bioMérieux (BIM.PA) could prove beneficial, especially as the company's innovations continue to address critical industry needs. Stakeholders should consider potential partnerships that can leverage the GENE-UP® TYPER, which could foster broader adoption and sustained revenue growth in the competitive landscape of food diagnostics.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Real-Time PCR* Solution Combines an Assay and a Web Application for Rapid Strain Characterization to Quickly Identify Root Cause Contamination Aiding in More Rapid Decision Making to Minimize Future Recurrence
MARCY-L'ÉTOILE, France , Feb. 13, 2025 /PRNewswire/ -- bioMérieux , a world leader in the field of in vitro diagnostics, today announces the launch of GENE-UP ® TYPER, a real-time, cutting-edge PCR solution for rapid pathogen detection root cause analysis in the food industry.
Each year, an estimated 600 million people fall ill after consuming contaminated food, according to the World Health Organization (WHO) 1 . These incidents not only pose serious health risks but also lead to costly recalls and reputational damage for food industries. Despite strict monitoring and control measures, contamination can still occur. By using root cause analysis solutions, food industries can identify breakdowns in processes and implement effective corrective actions to better prevent future contaminations.
GENE-UP ® TYPER is a real-time PCR solution for rapid strain characterization of microorganisms, for use on bioMérieux's GENE-UP ® system. This easy-to-use automated food pathogen detection solution helps speed up the decision-making process by providing faster insights on strain identity.
After a pathogen is detected during routine testing and the strains are isolated in a sample, DNA is extracted and amplified with the GENE-UP ® TYPER specific assay. The analytical result generated by the GENE-UP ® instrument is then transferred to the AUGMENTED-DX web application. Powered by machine learning, which combines cutting-edge algorithms with years of expertise embedded in a comprehensive genomic database, GENE-UP ® TYPER defines a unique address identifying the strain and groups identical strains into "clusters". The web application then progressively builds a history of the strain clusters present in the factory, allowing to trace back the source of contamination for an improved control of the production process.
"With more than 30 years of expertise in Industrial Applications, bioMérieux continues to heavily invest in disruptive science and technology to help the food processing industry keep pace with their rapidly changing environment. With GENE-UP ® TYPER, we bring to the market an innovative solution capable of rapidly identifying root causes through genomics and data utilization, participating in the collective effort to make the world a healthier place and fight against food insecurity. With our partner Mérieux NutriSciences, we share the same intent of reshaping the landscape of food safety and set augmented quality standards" , explains Yasha Mitrotti , Executive Vice President, Industrial Applications, bioMérieux.
This breakthrough and patented solution has been developed over years of research, with valuable contributions from Mérieux NutriSciences, a long-term partner of bioMérieux belonging to Institut Mérieux as well, and a global leader in food safety, quality and sustainability. Mérieux NutriSciences will retain co-exclusive rights to perform testing in key geographies for the outsourced testing services channel, ensuring the solution is available to all food and beverage processors, whether they operate an internal laboratory or outsource pathogen testing.
GENE-UP ® TYPER LMO, the first assay targeting Listeria monocytogenes root causes using the GENE-UP ® system, is now available worldwide for food manufacturers.
1 https://www.who.int/activities/estimating-the-burden-of-foodborne-diseases
* Polymerase Chain Reaction
ABOUT BIOMÉRIEUX
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2023, revenues reached €3.7 billion, with over 90% of sales outside of France .
bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in food, pharmaceutical and cosmetic products.
www.biomerieux.com .
bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP
CONTACTS
INVESTORS RELATIONS | ||
Aymeric Fichet | ||
Tel.: +33 (0)4 78 87 20 00 | ||
MEDIA RELATIONS | ||
CORPORATE | U.S. / INDUSTRIAL APPLICATIONS | FRANCE |
Romain Duchez | Maggie DiSantis | Laurence Heilbronn (Image 7) |
Tel.: +33 (0)4 78 87 20 00 | Tel. : +1 (331) 385-1332 | Tel.: +33 (0)1 53 70 74 48 |
SOURCE bioMérieux
FAQ**
How does the GENE-UP® TYPER system leverage machine learning to enhance the accuracy of identifying contamination sources in food industries, and what implications does this have for investors considering bioMérieux ADR BMXXY?
With the launch of GENE-UP® TYPER for Listeria monocytogenes, what competitive advantages does bioMérieux anticipate it will offer within the diagnostics market, and how might this affect the performance of bioMérieux ADR BMXXY?
How do the partnerships with organizations such as Mérieux NutriSciences influence the market reach and sales potential for bioMérieux's GENE-UP® TYPER, especially concerning bioMérieux ADR BMXXY?
Given the significant global burden of foodborne illnesses, what market growth opportunities does bioMérieux foresee for the GENE-UP® TYPER solution, and how could this impact the valuation of bioMérieux ADR BMXXY in the future?
**MWN-AI FAQ is based on asking OpenAI questions about Biomerieux ADR (OTC: BMXXY).
NASDAQ: BMXXY
BMXXY Trading
12.13% G/L:
$12.11 Last:
10,804 Volume:
$10.80 Open:
